United States Patent 12,201,638 (Drug) Scope, Claims, and Patent Landscape
What does US 12,201,638 claim cover?
US 12,201,638 claims a tightly defined, fixed-range solid oral dosage formulation defined by excipient identity plus quantitative weight ranges, plus dependent claim limits on tablet form and optional tablet coating.
Core claim (Claim 1): composition defined by drug plus excipient wt% bands
Claim 1 recites a pharmaceutical composition comprising components (a) through (f) where the weights add up to 100 wt%, with these ranges:
| Component |
Identity in claim |
Weight range in claim 1 |
| (a) |
Compound A: (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl) phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
3 to 15 wt% |
| (b) |
Microcrystalline cellulose |
55 to 70 wt% |
| (c) |
Dibasic calcium phosphate dihydrate |
18 to 22 wt% |
| (d) |
Sodium starch glycolate |
3.5 to 4.5 wt% |
| (e) |
Silicon dioxide |
0.05 to 0.50 wt% |
| (f) |
Glycerol behenate |
2.5 to 7 wt% |
| Total |
(a)-(f) |
100 wt% (explicit “add up to 100 wt%”) |
This is a classic “composition with numerical boundaries” claim: infringement hinges on meeting the same drug identity (Compound A) and landing within each wt% band, with a structural requirement that (a)-(f) total 100 wt%.
Dosage form and coating (Claims 2-3)
- Claim 2: composition of claim 1 in tablet form.
- Claim 3: the tablet further comprises a tablet coat.
These narrow the asserted embodiments toward solid oral tablets, including coated tablets.
Drug loading limits (Claims 4-8)
Claims 4-8 constrain the amount of Compound A in the final composition (not excipient wt% bands):
| Claim |
Additional constraint |
| Claim 4 |
Compound A 5 mg to 50 mg in the composition |
| Claim 5 |
Compound A 10 mg to 40 mg |
| Claim 6 |
Compound A is 10 mg |
| Claim 7 |
Compound A is 25 mg |
| Claim 8 |
Compound A is 40 mg |
Net effect: the patent simultaneously constrains (i) excipient identity and wt% ranges (Claim 1) and (ii) drug strength (Claims 4-8). The strongest posture is where both align: a tablet formulation that matches the wt% band set and contains one of the mg dose levels (10, 25, 40, or within broader mg intervals).
How hard is the claim boundary against design-arounds?
The claim structure creates multiple independent “knock-out” points for non-infringing formulations.
1) Must use the same Compound A identity
The drug substance in (a) is specified by full chemical identity. Any candidate that uses a different stereochemical form, different chemical entity, or a salt/prodrug that is not encompassed by the defined structure would not satisfy (a).
2) Must match excipient identity
Claim 1 requires each excipient listed:
- microcrystalline cellulose
- dibasic calcium phosphate dihydrate
- sodium starch glycolate
- silicon dioxide
- glycerol behenate
Replacing any excipient with a functionally similar alternative creates a clear boundary because the claim lists specific materials, not “pharmaceutically acceptable equivalents.”
3) Must fall within each wt% band simultaneously
To meet Claim 1, an accused product must satisfy all quantitative ranges at once:
- Compound A: 3 to 15 wt%
- microcrystalline cellulose: 55 to 70 wt%
- dibasic calcium phosphate dihydrate: 18 to 22 wt%
- sodium starch glycolate: 3.5 to 4.5 wt%
- silicon dioxide: 0.05 to 0.50 wt%
- glycerol behenate: 2.5 to 7 wt%
- sum total equals 100 wt%
This creates a narrow feasible formulation space. Even if one excipient stays within its range, moving another slightly outside breaks the claim.
4) Total sum requirement adds precision risk
The explicit “weights of components (a)-(f) add up to 100 wt%” tightens interpretation: if a formulation includes additional components not encompassed in the claim, the accused product would need to allocate them within the cited components or argue claim construction. In practice, this is often the single largest friction point for generic or follow-on formulations that add flavors, lubricants, coating polymers, or other excipients not listed in the claim.
5) Tablet and coating are additional limitations
Even if Claim 1 is met, Claim 2 requires tablet form and Claim 3 requires a tablet coat. Products in capsules or uncoated tablets would avoid those dependent claims, though Claim 1 could still be asserted if the formulation met the composition boundaries.
6) mg-per-tablet constraints control specific strengths
Claims 4-8 do not state “about” ranges beyond what is explicitly recited, and some claims lock to exact mg levels (Claim 6 at 10 mg; Claim 7 at 25 mg; Claim 8 at 40 mg). These are strong specificity points for product-by-product infringement analysis.
Claim chart logic for freedom-to-operate (FTO) screening
Minimal elements to check per product
A product must satisfy:
1) Compound A present in the recited identity
2) Tablet composition includes the required excipients
3) The wt% of each excipient matches the recited ranges
4) Total of components (a)-(f) equals 100 wt%
5) If asserting Claims 2-3, the dosage form is tablet and optionally coated
6) If asserting Claims 4-8, the mg amount of Compound A per composition matches the recited strength constraints
High-risk vs lower-risk paths (conceptual, product-focused)
- High-risk: formulation that matches the same excipient package (including glycerol behenate and sodium starch glycolate), stays within each wt% band, and markets strengths around 10 mg, 25 mg, or 40 mg.
- Lower-risk: formulations that change excipients (especially cellulose source, calcium phosphate form, disintegrant, or the lipid binder/coat agent specified by glycerol behenate), shift at least one excipient outside the band, or use a different dosage form (non-tablet) to avoid Claims 2-3.
What is the practical “scope” of the patent?
Scope is limited to formulation, not composition-of-method claims
The provided claims are composition claims. They cover:
- a formulation for tablets
- including optional tablet coat
- with specific excipient composition and drug load
They do not, on their face, claim:
- manufacturing steps
- dissolution profiles
- therapeutic methods
- dosing regimens
- polymorph, particle size, or process parameters (unless captured indirectly in “Compound A” identity or through additional unprovided claims)
Scope is narrow in material scope but broad in quantitative flexibility (within bands)
Claim 1 allows:
- Compound A 3 to 15 wt%
- cellulose 55 to 70 wt%
- calcium phosphate 18 to 22 wt%
- sodium starch glycolate 3.5 to 4.5 wt%
- silicon dioxide 0.05 to 0.50 wt%
- glycerol behenate 2.5 to 7 wt%
So within these ranges, many formulations could still fall within scope. The limiting factor is simultaneous compliance on all five excipient bands and the “100 wt%” total.
Where does this sit in a typical patent landscape?
How formulation patents generally function around a drug substance patent
In practice, a patent like US 12,201,638 commonly functions as a secondary/secondary-protection patent:
- It protects a specific tablet excipient system and numerical formulation boundaries for Compound A.
- It can block certain generics even when they have freedom on the active itself (or another earlier API patent expires), if they cannot land inside the wt% ranges or cannot avoid using the defined excipients.
Likely landscape pressure points for competitors
Because Claim 1 is strict, the landscape “pressure points” are:
- alternative excipient packages that avoid the enumerated set
- excipient substitution that changes wt% allocations so at least one falls outside the claimed band
- different dosage forms that do not fall under “tablet” or “coated tablet”
- strength planning to avoid mg level hits under Claims 4-8 (notwithstanding that mg claims are nested within Claim 1)
Read-through risk: dependent claims can create multiple landing zones
Even if a competitor avoids Claim 6 (10 mg exact), it may still infringe Claims 4-5 if it sits in 5-50 mg or 10-40 mg bands while meeting Claim 1. Similarly, avoiding coating might only remove Claim 3, not Claim 2 or Claim 1.
What additional information is needed to map the full patent landscape?
No more than the claims provided is needed to analyze scope of this specific patent’s claims (as above). A full landscape across:
- family members
- priority dates
- expiration and term adjustments
- other related formulation patents in the same family
- prosecution history and claim amendments
- Orange Book listed patents and FDA references
…cannot be produced from the claim text alone. Since this analysis must stay complete and accurate, it is limited to claim-scope and design-around logic for US 12,201,638 based on the claims supplied.
Key Takeaways
- US 12,201,638 Claim 1 is a formulation composition claim that requires Compound A plus a specific excipient set with simultaneous wt% bands and an explicit 100 wt% total across components (a)-(f).
- Dependent claims narrow further to tablet form (Claim 2) and coated tablets (Claim 3).
- Drug-strength constraints exist in Claims 4-8, including exact mg levels (10 mg, 25 mg, 40 mg), creating product-specific infringement risk for strengths that also satisfy Claim 1.
- Design-around leverage is structural: switching excipients away from the claimed list, pushing any excipient outside its band, or adding extra non-claimed components that break the “100 wt%” allocation can avoid Claim 1.
- Landscape value is primarily formulation protection: the patent is likely to impact competitors that can match the active but must redesign the tablet excipient system to avoid all claimed numerical boundaries.
FAQs
1) Does Claim 1 require a coating?
No. Claim 1 covers the composition. Coating is required only by Claim 3, which depends on Claim 2 (tablet form).
2) If a product matches Claim 1 but is not a tablet, does it infringe?
Claim 1 does not require tablet form. Tablet requirement is only in Claim 2. If the product is not a tablet, it may still face exposure under Claim 1 if the composition matches.
3) Can a competitor change microcrystalline cellulose type and still infringe?
If the product uses a cellulose that is not “microcrystalline cellulose” as required by Claim 1, it can fall outside. If it is still microcrystalline cellulose, it must also match the cellulose wt% band and all other limitations.
4) Which limitation is most difficult to design around: drug amount or excipient wt%?
Claim 1’s simultaneous wt% bands across multiple excipients plus the “add up to 100 wt%” condition creates tight constraints. Drug amount limits in Claims 4-8 add further product-specific constraints but are nested within Claim 1.
5) Does avoiding the 10 mg exact strength avoid infringement?
Avoiding Claim 6 alone does not avoid the patent if the product still meets Claim 1 and falls within Claim 4 or 5 (5-50 mg or 10-40 mg). Exact-strength avoidance helps only against the specific exact-mg dependent claims.
References
[1] Claim text provided in prompt: US Drug Patent 12,201,638 (Claims 1-8).
